In a phase II/III trial involving advanced HCC, another VEGFR-associated multi-targeted TKI donatinib achieved a superior OS over sorafenib (12.1 vs 10.3 months; HR 0.83; p = 0.0363) [113]. The gene discussed is KDR; the disease is hepatocellular carcinoma.